860506 | C6 Ceramide (d18:1/6:0)

N-hexanoyl-D-erythro-sphingosine


Powder

Size SKU Packaging Price
10mg 860506P-10mg 860506P-10mg 1 x 10mg $131.00
5mg 860506P-5mg 860506P-5mg 1 x 5mg $76.00
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
Please select an option above.
${sku} - ${concentration}

C6 Ceramide (d18:1/6:0)

C6 Ceramide (d18:1/6:0)

N-hexanoyl-D-erythro-sphingosine

Ceramide forms stable, fluid bilayers with cholesteryl phosphocholine, and this formulation has been shown to be more potent than solvent-delivered (DMSO) formulations of C6 Ceramide in inhibiting proliferation, inducing apoptosis, and disturbing calcium homeostasis.

Hygroscopic
No
Light Sensitive
No
Molecular Formula
C24H47NO3
Percent Composition
C 72.49%, H 11.91%, N 3.52%, O 12.07%
Purity
>99%
Stability
1 year
Storage Temperature
-20°C
CAS Number
124753-97-5
CAS Registry Number is a Registered Trademark of the American Chemical Society
Molecular Weight
397.635
Exact Mass
397.356
Synonyms
<p>N-(hexanoyl)-sphing-4-enine</p>
Complexation of C6-Ceramide with Cholesteryl Phosphocholine – A Potent Solvent-Free Ceramide Delivery Formulation for Cells in Culture (2013). Pramod Sukumaran , Max Lönnfors , Otto Långvik, Ilari Pulli, Kid Törnquist, J. Peter Slotte. [PLOS ONE] Flowers, M., G. Fabrias, A. Delgado, J. Casas, J.L. Abad, and M.C. Cabot. (2012). C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat 133:447-58. [PubMed]